PQR6XX (mTOR)

Indicaton

The brain-penentrant mTOR-only inhibitor PQR626 is currently in preclinical validation stage.

Therapeutic indications

CNS
Oncology

Type of product

Small molecule

Table

Phase

Discovery

You may also be interested in

OligoPhore / SemaPhore Peptide-Based RNA Delivery Platforms

Delivers siRNA, antisense oligonucleotides, mRNA and other mRNA modalities to extrahepatic tissues - demonstrated across various indications in oncology (e.g. PDAC, breast cancer, ovarian cancer, lung cancer, melanoma, ATLL, TME), and inflammatory / autoimmune diseases (e.g. OA, RA, enterocolitis), CV (e.g. atherosclerosis, aortic aneurysm)

Discovery

SOT201 (Immunocytokine, PD-1 x IL-15)

solid tumors

Phase I started

SOT109 (Antibody-Drug Conjugate)

solid tumors, mainly colorectal

Discovery